Bachelors and Teaching Degree in Biological Sciences from the School of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo (FFCLRP-USP), completed in 2012/14. In 2013, I completed an intercalated year of a BSc in Biotechnology at Newcastle University in Newcastle upon Tyne (United Kingdom) through the Science Without Borders program.PhD in Sciences from the Graduate Program in Pharmaceutical Sciences at the School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (FCFRP-USP), completed in 2020, including a sandwich period at the University of California, Davis in Sacramento (USA) in 2017, supported by FAPESP and CAPES scholarships.I have 15 years of experience in Research and Development, specializing in cell culture technologies, 3D cell culture, patient-derived tumor organoids (PDOs), and alternative methods to animal testing. During this time, I have participated in several research projects in collaboration with Hemocenter of Ribeirão Preto, School of Pharmaceutical Sciences of Ribeirão Preto, Ribeirão Preto Medical School Hospital, São Paulo State Cancer Institute (ICESP), In Situ Cell Therapy, and Fundação PIO XII Hospital de Amor in Barretos.In 2019, I founded the startup Living Out in vitro cell testing, aimed at developing an oncology diagnostic test to personalize treatment selection for colorectal cancer patients using patient-derived tumor organoids (PDTOs). I served as Principal Investigator for the companys RD projects until 2024. Currently, I remain a partner without salary or employment relationship. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Living Out intends to offer a personalized treatment planning service for oncology patients through in vitro functional exams. Living Out's target market is healthcare operators with vertical network management and large oncology care groups and hospitals. Living Out's main challenge today is to simulate our entire workflow in a real environment, from collecting tumor samples to issuing t…
In the conventional oncologic approach, patients with the same type of cancer are treated with similar drugs. However, clinical data often show that treatments may work well for some patients and not for others. This is because each patient has a unique profile, which results in different responses to the reference treatments. The use of patient-derived tumor organoids (PDOs) as predictiv…
The treatment of cancer with chemotherapy is an expensive approach and the patient may suffer from side effects of a treatment that, after months, proves to be ineffective. The reason is each patient is unique with a unique genetic profile, which leads to different responses to the reference treatments. The practice of personalized oncology is dedicated to finding the most appropriate tre…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing grants |
| 2 / 2 | Completed research grants |
| 1 / 1 | Ongoing scholarships in Brazil |
| 8 / 8 | Completed scholarships in Brazil |
| 12 / 12 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID
Google Scholar Citations